Home » Stocks » RGEN

Repligen Corporation (RGEN)

Stock Price: $213.30 USD -0.27 (-0.13%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $213.00 -0.30 (-0.14%) Apr 16, 7:07 PM
Market Cap 11.68B
Revenue (ttm) 366.26M
Net Income (ttm) 59.93M
Shares Out 52.55M
EPS (ttm) 1.11
PE Ratio 192.16
Forward PE 166.67
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $213.30
Previous Close $213.57
Change ($) -0.27
Change (%) -0.13%
Day's Open 214.18
Day's Range 211.95 - 214.46
Day's Volume 140,884
52-Week Range 102.13 - 228.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

These names are major disruptors in their respective industries. Could one of them be the next Tesla?

Other stocks mentioned: APPS, ETSY, LOVE, NIO, OKTA, TRUP
1 week ago - InvestorPlace

Financial media can often divert your attention away from the best investments.

Other stocks mentioned: ALGN, DXCM
2 weeks ago - The Motley Fool

These companies are set to keep riding upward thanks to long-term secular trends.

Other stocks mentioned: APPS, PYPL
3 weeks ago - The Motley Fool

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen (RGEN).

3 weeks ago - Zacks Investment Research

WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...

1 month ago - GlobeNewsWire

WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...

1 month ago - GlobeNewsWire

Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations.

1 month ago - Zacks Investment Research

Repligen (RGEN) beat estimates for both earnings and revenues in the fourth quarter of 2020.

1 month ago - Zacks Investment Research

Shares of Repligen (NASDAQ:RGEN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 160.00% year over year to $0.52, which beat the estimate of $0.31.

1 month ago - Benzinga

Repligen easily beat earnings and revenue views and guided high for the current fiscal year. RGEN stock jumped Wednesday.

1 month ago - Investors Business Daily

WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fou...

1 month ago - GlobeNewsWire

WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...

1 month ago - GlobeNewsWire

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

In the latest trading session, Repligen (RGEN) closed at $223.39, marking a +1.95% move from the previous day.

2 months ago - Zacks Investment Research

Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company...

2 months ago - GlobeNewsWire

On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

2 months ago - Zacks Investment Research

WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Protei...

2 months ago - GlobeNewsWire

Repligen (RGEN) closed the most recent trading day at $222.06, moving +1.9% from the previous trading session.

2 months ago - Zacks Investment Research

When it comes to coronavirus vaccines, think of Repligen as the man behind the curtain and RGEN stock as a tools powerhouse. Shares broke out of a cup base in January and hover in a buy zone.

2 months ago - Investors Business Daily

The tailwinds behind the company's gains aren't going anywhere.

3 months ago - The Motley Fool

WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...

3 months ago - GlobeNewsWire

The bioprocessing technology company gained momentum during the coronavirus pandemic.

3 months ago - The Motley Fool

Based on strong fundamentals, here we talk about four healthcare stocks to keep in your watchlist for 2021.

Other stocks mentioned: AZN, LHCG, QDEL
3 months ago - Zacks Investment Research

Invest in top-ranked stocks that are likely to beat earnings estimates in the upcoming releases.

Other stocks mentioned: CCRN, NTAP, OC, SPB
4 months ago - Zacks Investment Research

Is (RGEN) Outperforming Other Medical Stocks This Year?

4 months ago - Zacks Investment Research

WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 millio...

4 months ago - GlobeNewsWire

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public...

4 months ago - GlobeNewsWire

Repligen is a "pick-and-shovel" play in the bioprocessing industry. Repligen heavily invests in single-use products for use in downstream continuous manufacturing processes, which are two of the latest ...

4 months ago - Seeking Alpha

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock. In ...

4 months ago - GlobeNewsWire

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

Other stocks mentioned: ARPO, TCON
4 months ago - Zacks Investment Research

Is (RGEN) Outperforming Other Medical Stocks This Year?

4 months ago - Zacks Investment Research

Repligen (RGEN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Other stocks mentioned: IDXX, QDEL, VEEV
5 months ago - Investors Business Daily

These top-ranked stocks are likely to beat on bottom line in their next releases.

Other stocks mentioned: BJ, DG, HOLX, PH
5 months ago - Zacks Investment Research

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Other stocks mentioned: ALGN, PODD, QDEL, RMD
5 months ago - Investors Business Daily

The bioprocessing technology company is having a great year.

5 months ago - The Motley Fool

Repligen stock jumped 9% on the heels of the report to a new 52-week high of $203.90 today. And Louis Navellier sees a lot more upside for the company.

5 months ago - InvestorPlace

Repligen Corporation's (RGEN) CEO Tony Hunt on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Repligen (RGEN) delivered earnings and revenue surprises of 42.86% and 8.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a d...

5 months ago - GlobeNewsWire

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST -

5 months ago - GlobeNewsWire

Stocks Rally As Trump Set To Leave Hospital; Repligen, United Rentals, Marvell Tech Break Out

YouTube video

Trumps scheduled to leave the hospital and stocks recover from Friday’s sell off. Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing d...

Other stocks mentioned: MRVL, URI
6 months ago - Investors Business Daily

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

Other stocks mentioned: BGNE, EBS, HZNP
6 months ago - Zacks Investment Research

WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Protei...

6 months ago - GlobeNewsWire

Repligen: A Niche Play On Biologics

6 months ago - Seeking Alpha

Repligen hasn't seen quite the same tailwind from COVID-19 as some of its larger, more diversified rivals, but pandemic-related product development is still adding about 10% to sales.

6 months ago - Seeking Alpha

The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.

Other stocks mentioned: AZN, HZNP, LLY, RDY, ZTS
7 months ago - InvestorPlace

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput... [Read more...]

Industry
Medical Instruments & Supplies
Founded
1981
CEO
Anthony Hunt
Employees
1,128
Stock Exchange
NASDAQ
Ticker Symbol
RGEN
Full Company Profile

Financial Performance

In 2020, Repligen's revenue was $366.26 million, an increase of 35.53% compared to the previous year's $270.25 million. Earnings were $59.93 million, an increase of 179.88%.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Repligen stock is "Strong Buy." The 12-month stock price forecast is 236.71, which is an increase of 10.98% from the latest price.

Price Target
$236.71
(10.98% upside)
Analyst Consensus: Strong Buy